{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:33:51Z","timestamp":1777088031074,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"DOI":"10.7759\/cureus.107675","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:34:46Z","timestamp":1777084486000},"source":"Crossref","is-referenced-by-count":0,"title":["Identifying Flare Prone Spondyloarthritis: Insights From a Prospective Cohort"],"prefix":"10.7759","author":[{"given":"Abilash","family":"Krishnan V","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukesh Kumar","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urmila","family":"Dhakad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishant","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankush","family":"PM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puneet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209218","article-title":"Flare in axial spondyloarthritis. The dark side of the outcome","volume":"75","author":"Wendling D","year":"2016","unstructured":"Wendling D, Prati C. Flare in axial spondyloarthritis. The dark side of the outcome. Ann Rheum Dis. 2016, 75:950-1. 10.1136\/annrheumdis-2016-209218","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000883","article-title":"Defining and managing flares in axial spondyloarthritis","volume":"34","author":"Aouad K","year":"2022","unstructured":"Aouad K, Gossec L. Defining and managing flares in axial spondyloarthritis. Curr Opin Rheumatol. 2022, 34:195-202. 10.1097\/BOR.0000000000000883","journal-title":"Curr Opin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto A","year":"2018","unstructured":"Molto A, Gossec L, Meghnathi B, et al.. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis. 2018, 77:124-7. 10.1136\/annrheumdis-2017-212178","journal-title":"Ann Rheum Dis"},{"key":"ref4","article-title":"Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures","volume":"35","author":"Dougados M","year":"2017","unstructured":"Dougados M, Wood E, Gossec L, van der Heijde D, Logeart I. Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures. Clin Exp Rheumatol. 2017, 35:209-13.","journal-title":"Clin Exp Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.12.008","article-title":"Flare in spondyloarthritis: thresholds of disease activity variations","volume":"82","author":"Godfrin-Valnet M","year":"2015","unstructured":"Godfrin-Valnet M, Puyraveau M, Prati C, Wendling D. Flare in spondyloarthritis: thresholds of disease activity variations. Joint Bone Spine. 2015, 82:192-5. 10.1016\/j.jbspin.2014.12.008","journal-title":"Joint Bone Spine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep435","article-title":"Frequency and characteristics of disease flares in ankylosing spondylitis","volume":"49","author":"Cooksey R","year":"2010","unstructured":"Cooksey R, Brophy S, Gravenor MB, Brooks CJ, Burrows CL, Siebert S. Frequency and characteristics of disease flares in ankylosing spondylitis. Rheumatology (Oxford). 2010, 49:929-32. 10.1093\/rheumatology\/kep435","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial","volume":"71","author":"Song IH","year":"2012","unstructured":"Song IH, Althoff CE, Haibel H, et al.. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012, 71:1212-5. 10.1136\/annrheumdis-2011-201010","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20987700","article-title":"Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial","volume":"13","author":"Proft F","year":"2021","unstructured":"Proft F, Wei\u00df A, Torgutalp M, et al.. Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. Ther Adv Musculoskelet Dis. 2021, 13:1759720X20987700. 10.1177\/1759720X20987700","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00761-z","article-title":"Treatment of axial spondyloarthritis: an update","volume":"18","author":"Danve A","year":"2022","unstructured":"Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022, 18:205-16. 10.1038\/s41584-022-00761-z","journal-title":"Nat Rev Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182514093","article-title":"Economic considerations of the treatment of ankylosing spondylitis","volume":"343","author":"Reveille JD","year":"2012","unstructured":"Reveille JD, Ximenes A, Ward MM. Economic considerations of the treatment of ankylosing spondylitis. Am J Med Sci. 2012, 343:371-4. 10.1097\/MAJ.0b013e3182514093","journal-title":"Am J Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-7045624\/v1","article-title":"Identifying flare prone Spondyloarthritis-insights from a prospective cohort","author":"Vijayakumaran AK","year":"2025","unstructured":"Vijayakumaran AK, Mukherjee S, Dhakad U, Maurya MK, Kamble N, PM A, Kumar P. Identifying flare prone Spondyloarthritis-insights from a prospective cohort. 2025, 10.21203\/rs.3.rs-7045624\/v1"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68 Suppl 2","author":"Sieper J","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, et al.. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009, 68 Suppl 2:ii1-44. 10.1136\/ard.2008.104018","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs DA","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005, 140:509-16. 10.1016\/j.ajo.2005.03.057","journal-title":"Am J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213609","article-title":"Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative","volume":"77","author":"Balint PV","year":"2018","unstructured":"Balint PV, Terslev L, Aegerter P, et al.. Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative. Ann Rheum Dis. 2018, 77:1730-5. 10.1136\/annrheumdis-2018-213609","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab082","article-title":"Understanding flare in axial spondyloarthritis: novel insights from daily self-reported flare experience","volume":"5","author":"Barnett R","year":"2021","unstructured":"Barnett R, Ng S, Sengupta R. Understanding flare in axial spondyloarthritis: novel insights from daily self-reported flare experience. Rheumatol Adv Pract. 2021, 5:rkab082. 10.1093\/rap\/rkab082","journal-title":"Rheumatol Adv Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11174","article-title":"Patient-reported disease activity in an axial spondyloarthritis cohort during the COVID-19 pandemic","volume":"2","author":"Liew JW","year":"2020","unstructured":"Liew JW, Castillo M, Zaccagnino E, Katz P, Haroon N, Gensler LS. Patient-reported disease activity in an axial spondyloarthritis cohort during the COVID-19 pandemic. ACR Open Rheumatol. 2020, 2:533-9. 10.1002\/acr2.11174","journal-title":"ACR Open Rheumatol"},{"key":"ref17","article-title":"Definition of disease flare in ankylosing spondylitis: the patients\u2019 perspective","volume":"29","author":"Brophy S","year":"2002","unstructured":"Brophy S, Calin A. Definition of disease flare in ankylosing spondylitis: the patients\u2019 perspective. J Rheumatol. 2002, 29:954-8.","journal-title":"J Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160838","article-title":"Patient-reported flares in ankylosing spondylitis: a cross-sectional analysis of 234 patients","volume":"44","author":"Jacquemin C","year":"2017","unstructured":"Jacquemin C, Maksymowych WP, Boonen A, Gossec L. Patient-reported flares in ankylosing spondylitis: a cross-sectional analysis of 234 patients. J Rheumatol. 2017, 44:425-30. 10.3899\/jrheum.160838","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae138","article-title":"Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: a nationwide cohort study","volume":"64","author":"Yeo J","year":"2025","unstructured":"Yeo J, Kim JY, Park JK, Shin K, Lee EY, Kim TH, Park JW. Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: a nationwide cohort study. Rheumatology (Oxford). 2025, 64:1155-61. 10.1093\/rheumatology\/keae138","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0495","article-title":"Occurrence and prediction of flare after tapering of tumor necrosis factor inhibitors in patients with axial spondyloarthritis","volume":"51","author":"Wetterslev M","year":"2024","unstructured":"Wetterslev M, Georgiadis S, Nysom Christiansen S, et al.. Occurrence and prediction of flare after tapering of tumor necrosis factor inhibitors in patients with axial spondyloarthritis. J Rheumatol. 2024, 51:39-49. 10.3899\/jrheum.2023-0495","journal-title":"J Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3726-2","article-title":"TNF\u03b1 blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in spondyloarthritis","volume":"36","author":"Nair AM","year":"2017","unstructured":"Nair AM, Sandhya P, Yadav B, Danda D. TNF\u03b1 blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in spondyloarthritis. Clin Rheumatol. 2017, 36:2243-51. 10.1007\/s10067-017-3726-2","journal-title":"Clin Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05433-5","article-title":"Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study","volume":"40","author":"Ganapati A","year":"2021","unstructured":"Ganapati A, Gowri M, Antonisamy B, Danda D. Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study. Clin Rheumatol. 2021, 40:1871-9. 10.1007\/s10067-020-05433-5","journal-title":"Clin Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470919-identifying-flare-prone-spondyloarthritis-insights-from-a-prospective-cohort","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:34:52Z","timestamp":1777084492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470919-identifying-flare-prone-spondyloarthritis-insights-from-a-prospective-cohort"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.107675","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}